Active, Not Recruiting
Long-term Experience With Abatacept SC in Routine Clinical Practice - IM101-348
Updated: 13 November, 2018 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
Inclusion Criteria: - Patients ≥18 years old at treatment initiation - Patients diagnosed with established moderate to severe active RA as per the 1987 ACR criteria/2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Rheumatoid Arthritis Classification Criteria - Patients naïve of Abatacept IV and who at their physician's discretion are initiated with Abatacept SC. In countries where required (e.g. Germany and Spain), patients naïve of Abatacept IV and who at their physician's discretion have been initiated with Abatacept SC at least 1 month prior to enrollment visit up to 6 months if baseline and disease characteristics data are available - For Spanish pharmacogenomic sub-study: - Caucasian patient and from European ancestry - Patient for whom a collection of blood sample before the initiation of abatacept is possible or available (blood sample was taken in routine practice before the study enrolment) - Patient who agreed to participate in this substudy and provide a specific signed Pharmacogenomic Blood RNA informed consent - In the UK, the ART substudy will be proposed to all patients enrolled in ASCORE from amendment approval and application date Exclusion Criteria: - Patients who are currently included in any interventional clinical trial in RA
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
